A Systematic Review of Vinorelbine for the Treatment of Breast Cancer

Xu, Yingchun; Wang, Hongxia; Tang, Lei; Ma, Yue; Zhang, Fengchun

doi:10.1111/tbj.12071

Cited by 32 publications

(38 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast cancer is one of the most heterogeneous tumors, presenting various histologies, behaviors and outcomes (1)(2)(3)(4)(5). Patients with similar clinicopathological characteristics can have markedly different outcomes.…”

Section: Introductionmentioning

confidence: 99%

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients

Zhang

et al. 2015

Oncology Reports

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients

Zhang

et al. 2015

Oncology Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…NVB has been evaluated in NSCLC in the adjuvant and advanced settings as a single agent and in combination with other agents (typically a platinum or gemcitabine) with modest success (16). In the present study, we detected the effects of combination of TRAIL and NVB on A549 cells and lung carcinoma-xenograft nude mice.…”

Section: Discussionmentioning

confidence: 79%

TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer

et al. 2014

View full text Add to dashboard Cite

Abstract. Non-small cell lung cancer (NSCLC) is relatively insensitive to chemotherapy. NP [vinorelbine (NVB) + cisplatin] is the standard chemotherapy regimen in clinical treatment; however, its side-effects are intolerable for most patients. In some reports, the TNF-related apoptosis-inducing ligand (TRAIL) can enhance the sensitivity of chemotherapy drugs by inducing apoptosis without toxicity to normal cells. In the present study, we evaluated the antitumor effects of the two drugs (TRAIL and NVB alone or in combination) by inducing apoptosis in vitro and in vivo. Using the human NSCLC cell line (A549) and a BALB/c nude mice model, we observed the cell viability (MTT assay), cell apoptosis [Hoechst staining, Annexin V/propidium iodide (PI) staining assay, immunohistochemical staining, RT-PCR and western blotting] and cell proliferation (soft agar colony formation and cell cycle assay). The results showed that TRAIL and NVB alone inhibited tumor growth both in vivo and in vitro. However, the combination of the two drugs produced a more potent antitumor effect (P<0.05) and caused more severe apoptosis in tumor tissue (P<0.05). The key molecular protein level of the mitochondrial apoptotic pathway (Bax and caspase-3) was further upregulated by the combination of the two drugs (P<0.01) and either drug alone (P<0.05). The mRNA level of Bcl-2 and Bax in the combination group was downregulated and upregulated respectively, when compared with the control group (P<0.01). The combination group of A549 cells also showed lower viability compared with the one drug alone group (P<0.05). Moreover, the Hoechst staining assay and Annexin V/PI staining assay showed that the combination of the two drugs induced a more potent apoptosis than either drug alone (P<0.05, early apoptosis P<0.01, respectively). In addition, the cell colony numbers were deduced after treatment with TRAIL or NVB alone (P<0.05) and the two drug combination (P<0.01). Cell cycle analysis showed that TRAIL and NVB alone markedly increased the percentage of cells in G1 phase (P<0.05) and the combination of the two drugs decreased the percentage of cells in G2 and S phase (P<0.05). Thus, the combination of TRAIL and NVB can inhibit lung cancer cell growth by affecting the level of key signaling protein expression of the apoptosis pathway.

show abstract

“…Oral formulations are not currently available for use in North America. Phase ii trials of vinorelbine have demonstrated varied rrs in the abc setting (25%-47%), depending on the line of therapy 84,85 .…”

Section: Vinorelbinementioning

confidence: 99%

Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines

et al. 2015

View full text Add to dashboard Cite

Despite advancements in the treatment of early-stage breast cancer, many patients still develop disease recurrence; others present with de novo metastatic disease. For most patients with advanced breast cancer, the primary treatment intent is noncurative—that is, palliative—in nature. The goals of treatment should therefore focus on maximizing symptom control and extending survival. Treatments should be evaluated on an individualized basis in terms of evidence, but also with full respect for the wishes of the patient in terms of acceptable toxicity. Given the availability of extensive reviews on the roles of endocrine therapy and her2 (human epidermal growth factor receptor 2)–targeted therapies for advanced disease, we focus here mainly on treatment guidelines for the non-endocrine management of her2-negative advanced breast cancer in a Canadian health care context.

show abstract

A Systematic Review of Vinorelbine for the Treatment of Breast Cancer

Cited by 32 publications

References 35 publications

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients

TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer

Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines

Contact Info

Product

Resources

About